UVA researchers identify key blood biomarkers linked to SIDS, paving the way for life-saving tests to detect and prevent this leading cause of death among infants.

Eligible schools have the opportunity to receive 2 cartons of epinephrine nasal spray for use in emergency situations to treat type I allergic reactions, including anaphylaxis.

"In aggregation with other robust observational studies, these results can inform the management of asthma and allergic rhinitis in this patient group," wrote the study authors.

"The greatest risk reductions were demonstrated in those who experienced obesity remission during childhood," stated study authors.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

HHS selects 15 more Medicare Part D drugs for price negotiation under the Inflation Reduction Act, aiming to lower costs for millions by 2027.

Read these quick comments from Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, and Bernard Cohen, MD, regarding the banning of red No. 3 from foods and ingested drugs.

The digestive enzyme cartridge is designed to mimic pancreatic lipase function.

A CDC report shows only 23% of U.S. teens get enough sleep, with disparities highlighting the need for targeted health interventions.

Across all years in the report, the CDC rated each physical activity trend with a color of red, indicating that trends are going in the "wrong direction."

Manufacturers who use red no. 3 in food and and ingested drugs will have until January 15, 2027 or January 18, 2028, respectively, to reformulate their products.

Colleen Sloan, PA-C, RDN, explores how diet can help manage childhood constipation.

According to the report, several key dietary behaviors such as daily fruit or vegetable intake among high school students were trending in the wrong direction.

The lead clinical trial investigator for a phase 3 study of crinecerfont in pediatric CAH patients breaks down the December 2024 FDA approval.

Of those with a minimum age or minimum interval vaccine dose, 44.9% ended up receiving extra doses to complete a vaccination series.

Neffy was first approved in September 2024 to treat type 1 allergic reactions in patients who weigh at least 66 lbs (33 kg).

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

In an open-label extension of the EPITOPE phase 3 trial, the Viaskin Peanut patch had continued improvement in toddlers aged 1-3 years through 36 months.

Based on reports by NoroSTAT-participating states, the total number of outbreaks in 2024-2025 seasonal year is above the range reported 012–2020 and 2021-2024 seasonal years.

The study within a single health care system revealed that most infants born prior to December received the nirsevimab monoclonal antibody.

A recent study highlights potential reductions in macronutrient levels in breast milk because of maternal medications, though breastfeeding remains strongly recommended.

Recent research evaluated the association between screen time and autism spectrum disorder by considering socioeconomic factors as instrumental variables.

In this cross-sectional population of insured adolescents from 2018 to 2022, receipt of puberty blockers and hormones was rare.

Medical advice was sought on the fifth day of symptoms, and by this time, the child was improving clinically.